New York, New York-- (Newsfile Corp. - February 7, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Novo Nordisk (NYSE: NVO) and certain ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Find insight on Novo Nordisk, GSK and more in the latest Market Talks covering Health Care.

Text messages show Elon Musk rejected a dinner invite from Nicolai Tangen, head of Norway's oil fund, and lectured him on how ...

Moderna and Novo Nordisk are once again in the bad books ... in COVID-19 vaccine trial Moderna’s case centered on a 2023 meeting attended by 56 healthcare professionals from 20 countries to ...

Financial report for the period 1 January 2024 to 31 December 2024 Operating profit increased by 25% in Danish kroner and by ...

Novo Nordisk's strong stock performance and analysts' high revenue projections have set a high bar for the company's future performance. Meeting these expectations may become challenging ...